In This Article:
Genetic Networks Signs MOU with UMAV
WEWAHITCHKA, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- UAV Corp (OTC: UMAV), a leader in unmanned aerial vehicle (UAV) technology, and Genetic Networks, a wholly owned subsidiary of Fifty 1 Labs, Inc. (OTC: FITY) and a pioneer in genetic perturbation and drug discovery, are excited to announce the signing of a Memorandum of Understanding (MOU) on April 07, 2025. This strategic partnership aims to develop innovative solutions for detecting and countering biohazards, contaminants, and related threats, leveraging UAV Corp’s advanced aerial systems and Genetic Networks’ proprietary GeneScape™ platform to enhance public safety, health, and security globally.
The collaboration integrates state-of-the-art “sniffer” technologies into UAV Corp’s airships and drones, enabling real-time detection of nuclear, chemical, and biological hazards. Genetic Networks, under the umbrella of Fifty 1 Labs, Inc. (OTC: FITY), contributes its expertise in biohazard identification and drug development—including a patented compound with potential broad-spectrum efficacy against infections—to create countermeasures deployable via UAV Corp’s aerial platforms. Initial testing will occur on UAV Corp’s airship, currently under completion at its Wewahitchka facility, advancing aerial threat response capabilities.
Both companies are actively engaged in Department of Defense (DoD) contracts, positioning them to assist each other in meeting stringent government requirements. UAV Corp’s UAV expertise complements Genetic Networks’ advancements in genetic science, offering mutual support for DoD initiatives. On April 1, 2025, FITY announced a groundbreaking yeast experiment launched on SpaceX’s Fram2 mission, engineered by Dr. Corey Nislow to study resistance to microgravity and cosmic radiation—data that could inform this collaboration’s countermeasure development. Genetic Networks will facilitate introductions between their relationships and UMAV’s management team to potentially unlock new opportunities for contracts and collaborations in the defense and space sectors.
“This partnership merges cutting-edge aerial technology with genetic innovation to tackle critical global challenges,” said Michael Lawson, CEO of UAV Corp. “By equipping our UAV platforms with advanced detection systems and collaborating with Genetic Networks, we’re set to deliver rapid, impactful solutions to biohazard threats worldwide while strengthening our DoD efforts and exploring new avenues.”
Gennaro D’Urso, Founder, CEO, and Chairman of Genetic Networks, added, “Teaming up with UAV Corp amplifies the reach of our GeneScape™ platform and drug development efforts, as demonstrated by our recent SpaceX Fram2 mission experiment under Fifty 1 Labs, Inc. (OTC: FITY). Together, we’re poised to detect dangers and deploy life-saving countermeasures efficiently, utilizing our supplier network of approximately 4,000 generic formulations and supporting our shared DoD objectives.”